Home
Investing
Stocks
USA
NASDAQ
Phathom Pharmaceuticals Inc (PHAT)
Phathom Pharmaceuticals Inc (PHAT) News

Phathom Pharmaceuticals Inc (PHAT)

7.95

-0.37

(-4.45%)

Closed July 19 4:00PM

7.99

0.04

(0.50%)

After Hours: 7:59PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Form 4 - Statement of changes in beneficial ownership of securities

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...

Form 8-K - Current report

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

FLORHAM PARK, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...

Form 8-K - Current report

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today...

Form 4 - Statement of changes in beneficial ownership of securities

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

fsulevine 1 month ago

There is nothing greater in investing than watching the shorts of a stock you own lose their shorts!! Got my investment back, plus a little bit… and I still have just over 1/2 the shares I owned! Hopefully it will go to the moon!

👍 1

glenn1919 2 months ago

PHAT..........................................https://stockcharts.com/h-sc/ui?s=PHAT&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 2 months ago

PHAT....................................https://stockcharts.com/h-sc/ui?s=PHAT&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 2 months ago

PHAT.....................................................https://stockcharts.com/h-sc/ui?s=PHAT&p=W&b=5&g=0&id=p86431144783

👍️0

rolvram 7 months ago

Blackrock keeps accumulating
https://stockzoa.com/ticker/phat/ownership/blackrock/#google_vignette

👍️0

Monksdream 10 months ago

PHAT new 52=high

👍️0

MiamiGent 11 months ago

PHAT Nice! Account increased 11%! Was stacked.

👍️0

MiamiGent 11 months ago

PHAT 28.5% Revenue beat!

👍️0

MiamiGent 12 months ago

PHAT Still in.

👍️0

FALCON1 12 months ago

https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri

https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation

👍️0

MiamiGent 1 year ago

HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
BENZINGA

Jul-19-2024 6:41 a.m. ET

HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (PHAT) with a Buy and maintains $28 price target.

BRIEF-Phathom Pharmaceuticals Announces FDA Approval Of Voquezna® (Vonoprazan) Tablets For The Relief Of Heartburn Associated With Non-Erosive Gerd In Adults
REUTERS

Jul-18-2024 8:41 a.m. ET

July 18 (Reuters) - Phathom Pharmaceuticals Inc (PHAT) :

* PHATHOM PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF VOQUEZNA® (VONOPRAZAN) TABLETS FOR THE RELIEF OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GERD IN ADULTS

* PHATHOM PHARMACEUTICALS INC (PHAT): VOQUEZNA MET ITS PRIMARY ENDPOINT IN ITS PHASE 3 PIVOTAL TRIAL Source text for Eikon: Further company coverage:

Monksdream 1 year ago

PHAT under $10

👍️0

Monksdream 1 year ago

Phathom Pharmaceuticals

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Phathom Pharmaceuticals Inc (PHAT)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.